For the third time this yr, a affected person handled with a Sarepta Therapeutics gene remedy has died, a revelation that comes as the corporate tries to earn again affected person and investor belief amid a collection of security setbacks.
The first two fatalities had been teenage boys handled with the commercialized Duchenne muscular dystrophy gene remedy Elevidys. The newest fatality was a 51-year-old man who obtained SRP-9004, an experimental gene remedy for limb-girdle muscular dystrophy 2D/R3. All three sufferers died after creating acute liver failure.
BioCentury first reported the newest fatality late Thursday. Sarepta confirmed the event, then held a convention name on Friday, throughout which monetary analysts peppered executives with questions on why they didn’t disclose the fatality Wednesday, when the corporate introduced a cash-saving company restructuring that can minimize 36% of its workers and cease additional growth of two limb girdle packages, together with SRP-9004.
Sarepta CEO Doug Ingram defended the corporate’s degree of disclosure, telling analysts that the fatality was not a fabric occasion nor was it central to the subjects mentioned Wednesday. He added that the corporate’s determination to not proceed with the 2 limb-girdle packages was monetary, and was made unbiased of the fatality. Ingram defined that there was no additional dosing within the limb-girdle examine, so the right approach to talk about the fatality could be within the presentation of the complete examine outcomes, which Sarepta plans to do at a future medical assembly.
“As pertains to materiality, definitely if there was a fabric change within the security sign of one in every of our marketed therapies, we might disclose that publicly,” Ingram mentioned. “I feel we’ve got, I imagine, a really laudable historical past of being terribly clear, not solely with the doctor and affected person neighborhood, however with our investor base as properly.”
Louise Rodino-Klapac, the corporate’s head of R&D and chief scientific officer, mentioned the deceased limb-girdle affected person was a 51-year-old, non-ambulatory man. The demise occurred a month in the past, about 11 weeks after dosing. Rodino-Klapac mentioned Sarepta notified the FDA first in regards to the life-threatening liver complication, then in regards to the demise.
“The FDA was correctly knowledgeable alongside the way in which of this case,” she mentioned.
One other analyst requested whether or not Sarepta is conscious of some other fatalities related to its gene therapies. Rodino-Klapac replied no.
Regardless of Ingram’s clarification, analysts and buyers see the developments with SRP-9004 as materials and related to the corporate and to Elevidys. Sarepta’s gene therapies are delivered to their locations within the physique aboard adeno-associated viruses (AAV). Adversarial reactions are a identified danger of genetic medicines that use these engineered viruses. In a analysis be aware, Leerink Companions analyst Joseph Schwartz famous that the AAV vector used for SRP-9004 is identical one utilized in Elevidys. It’s additionally utilized in SRP-9003, a Sarepta gene remedy candidate for one more type of limb-girdle muscular dystrophy. Sarepta plans to file an software later this yr searching for FDA approval of SRP-9003.
William Blair analyst Sami Corwin mentioned in a analysis be aware that given the deceased limb-girdle affected person’s age, the excessive dose of the AAV-based gene remedy was the possible reason for the liver failure. She mentioned this fatality might result in larger scrutiny of SRP-9003. It might additionally amplify hesitancy of Duchenne sufferers to make use of Elevidys and enhance investor mistrust because of the failure to reveal the demise, she mentioned.
In one other analysis be aware, Corwin mentioned William Blair believes the dearth of transparency from Sarepta administration is contributing to the corporate’s inventory worth decline. Shares closed Friday at $14.07, down practically 36% from Thursday’s shut. Corwin added that the dearth of transparency is dangerous to the AAV gene remedy subject extra broadly.
Elevidys initially gave the impression to be a shiny spot in Sarepta’s company shakeup announcement. The corporate mentioned Wednesday that the FDA requested for a label replace to incorporate a black field warning, which analysts interpreted as optimistic as a result of it suggests the product gained’t be pulled from the market. However Elevidys won’t be accessible to Duchenne sufferers for much longer. The FDA will ask Sarepta to cease all shipments of the gene remedy, Reuters reported Friday afternoon, citing an unnamed supply accustomed to the matter. The FDA has been investigating the fatalities related to Elevidys, an inquiry it introduced in late June following the report of the second demise.
In a be aware despatched to buyers after Friday’s market shut, Leerink’s Schwartz mentioned his agency is just not assured that Sarepta understands the liver security sign sufficient to establish a affected person inhabitants the place the protection danger is suitable. He added the FDA could need to make an instance of Elevidys and removing of the product from the market is turning into a respectable danger. Leerink can now not advocate Sarepta’s inventory “beneath any circumstances.”
“We strongly disagree with administration relating to their opinion on the materiality of the third demise for his or her gene remedy platform, and once more we predict this considerably undermines their credibility,” Schwartz mentioned. “We additionally disagree with administration’s opinion that this demise doesn’t have readthrough to Elevidys and see mounting industrial danger for that program following one other gene remedy demise.”
On Friday afternoon, the FDA positioned medical holds on Sarepta’s limb-girdle research and requested the corporate to voluntarily cease all shipments of Elevidys. The regulator additionally revoked the platform know-how designation for the know-how that Sarepta used to develop its gene therapies. The FDA mentioned given the brand new data, the preliminary proof is inadequate to point out that this know-how can be utilized safely in one other remedy.
Sarepta is just not stopping shipments of Elevidys. In a assertion issued Friday night, Sarepta mentioned its interpretation of the scientific information exhibits no new or modified security alerts in ambulatory Duchenne sufferers and the corporate will proceed to provide the gene remedy for therapy of this affected person group.
(Story up to date all through with further analyst feedback, FDA motion, and Sarepta response.)
Picture: Michael Nagle/Bloomberg, through Getty Pictures
